ABOUT US
CUTTING-EDGE THERAPEUTICS

Scroll down to see more

About Laekna

Founded in December 2016, Laekna Therapeutics is an emerging innovative biotech company based in Zhangjiang Pharma Valley in Shanghai, China and New Jersey, USA. It focuses on developing ground-breaking innovative therapies to treat cancer and liver diseases.



Laekna Therapeutics is adopting a two-pronged strategy in new product development. The company enriches its pipeline by obtaining the global licenses of novel drug candidates in the clinical stage of development for which safety and anti-cancer efficacy have been assessed. The company has obtained the global licenses of four new medicine candidates from Novartis. Meanwhile, Laekna is also establishing its internal product discovery team with multiple preclinical stage molecules. The most advanced molecules will apply for IND and soon move forward to clinical development stages.



Laekna leadership team members have over 20 years of experience in new medicine discovery and development in both China and the US, with an exceptional track record in R&D, new drug approvals and commercialization. Laekna has built its research and clinical development team by attracting top experts from global and local pharmaceutical or biotech companies. Laekna is committed to taking a science-based, innovation-driven approach to build its clinical R&D pipeline, and develop first-in-class and best-in-class innovative medicines. It has been developing an international platform for new product research and development to benefit patients.

  1. An emerging

    innovative biotech

    company based in

    Zhangjiang Pharma

    Valley in Shanghai,

    China and New

    Jersey, USA

  2. Focused on developing

    groundbreaking

    innovative therapies

    to treat cancer

    and liver diseases

  3. Striving for

    First-in-Class and

    Best-in-Class

    pharmaceuticals

Management Team
Milestones
2016

December, Laekna established

2017

June, Acquired global licenses of LAE001  

2018

May, Completed Series A financing

May, Acquired global licenses of LAE002 & LAE003

2019

August, Completed Series B financing

2020

February, Acquired global licenses of LAE005

October, Completed series C financing

2021

October, Complete series D financing

2022

Upcoming

Q4 1st NDA to be submitted in China and the US

Q4 First internally discovered asset to start global clinical trial

2023

Upcoming

Q2 GMP commercial production site in Lingang, Shanghai to start operation

Lab at Zhangjiang Hi-Tech Park
Honors &
Awards
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin